One study found that the infection rate in the abatacept group was lower compared to the adalimumab group, although this difference did not reach statistical significance.
← all excerpts
Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study.
1
—
—